<?xml version='1.0' encoding='utf-8'?>
<document id="25047497"><sentence text="Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers."><entity charOffset="10-22" id="DDI-PubMed.25047497.s1.e0" text="ketoconazole" /><entity charOffset="26-39" id="DDI-PubMed.25047497.s1.e1" text="lobeglitazone" /><pair ddi="false" e1="DDI-PubMed.25047497.s1.e0" e2="DDI-PubMed.25047497.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25047497.s1.e0" e2="DDI-PubMed.25047497.s1.e1" /></sentence><sentence text="Lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, is metabolized primarily by the cytochrome P450 (CYP) 3A4 isoenzyme"><entity charOffset="0-13" id="DDI-PubMed.25047497.s2.e0" text="Lobeglitazone" /></sentence><sentence text=" Individuals concomitantly taking lobeglitazone and a CYP3A4 inhibitor may experience some adverse effects secondary to increased systemic exposure to lobeglitazone"><entity charOffset="34-47" id="DDI-PubMed.25047497.s3.e0" text="lobeglitazone" /><entity charOffset="151-164" id="DDI-PubMed.25047497.s3.e1" text="lobeglitazone" /><pair ddi="false" e1="DDI-PubMed.25047497.s3.e0" e2="DDI-PubMed.25047497.s3.e0" /><pair ddi="true" e1="DDI-PubMed.25047497.s3.e0" e2="DDI-PubMed.25047497.s3.e1" /></sentence><sentence text=" To address such potential concern, we evaluated the effects of ketoconazole, a prototypic CYP3A4 inhibitor, on the pharmacokinetic (PK) properties and associated adverse effects of lobeglitazone"><entity charOffset="64-76" id="DDI-PubMed.25047497.s4.e0" text="ketoconazole" /><entity charOffset="182-195" id="DDI-PubMed.25047497.s4.e1" text="lobeglitazone" /><pair ddi="false" e1="DDI-PubMed.25047497.s4.e0" e2="DDI-PubMed.25047497.s4.e0" /><pair ddi="true" e1="DDI-PubMed.25047497.s4.e0" e2="DDI-PubMed.25047497.s4.e1" /></sentence><sentence text="" /><sentence text="A PK drug-drug interaction study was conducted in healthy individuals between 20 and 45 years old in a randomized, open-label, 2-way crossover design" /><sentence text=" Even though the PK study was performed on a single dose of lobeglitazone, multiple ketoconazole doses were given to ensure that the full extent of inhibition of CYP3A4 was maintained during the PK sampling"><entity charOffset="60-73" id="DDI-PubMed.25047497.s7.e0" text="lobeglitazone" /><entity charOffset="84-96" id="DDI-PubMed.25047497.s7.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25047497.s7.e0" e2="DDI-PubMed.25047497.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25047497.s7.e0" e2="DDI-PubMed.25047497.s7.e1" /></sentence><sentence text=" All study participants received a single oral dose of lobeglitazone 0"><entity charOffset="55-68" id="DDI-PubMed.25047497.s8.e0" text="lobeglitazone" /></sentence><sentence text="5 mg with or without 9 oral 200-mg doses of ketoconazole pretreatment twice daily"><entity charOffset="44-56" id="DDI-PubMed.25047497.s9.e0" text="ketoconazole" /></sentence><sentence text=" The primary PK parameter end points (AUC and Cmax) were estimated using noncompartmental analysis, and the 90% CIs for the geometric mean ratios (ratio of lobeglitazone and ketoconazole to lobeglitazone alone) were investigated"><entity charOffset="156-169" id="DDI-PubMed.25047497.s10.e0" text="lobeglitazone" /><entity charOffset="174-186" id="DDI-PubMed.25047497.s10.e1" text="ketoconazole" /><entity charOffset="190-203" id="DDI-PubMed.25047497.s10.e2" text="lobeglitazone" /><pair ddi="false" e1="DDI-PubMed.25047497.s10.e0" e2="DDI-PubMed.25047497.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25047497.s10.e0" e2="DDI-PubMed.25047497.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25047497.s10.e0" e2="DDI-PubMed.25047497.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25047497.s10.e1" e2="DDI-PubMed.25047497.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25047497.s10.e1" e2="DDI-PubMed.25047497.s10.e2" /></sentence><sentence text=" Tolerability (adverse events, vital signs, ECG, and laboratory tests) was also assessed" /><sentence text="" /><sentence text="A total of 24 Korean men (mean age, 26 years; age range, 20-32 years; mean weight, 68 kg; weight range, 59-81 kg) completed the study and were evaluable for lobeglitazone PK properties and tolerability"><entity charOffset="157-170" id="DDI-PubMed.25047497.s13.e0" text="lobeglitazone" /></sentence><sentence text=" The mean (SD) Cmax values of lobeglitazone with and without ketoconazole were 49 (7) ng/mL and 48 (6) ng/mL at 1"><entity charOffset="30-43" id="DDI-PubMed.25047497.s14.e0" text="lobeglitazone" /><entity charOffset="61-73" id="DDI-PubMed.25047497.s14.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25047497.s14.e0" e2="DDI-PubMed.25047497.s14.e0" /><pair ddi="false" e1="DDI-PubMed.25047497.s14.e0" e2="DDI-PubMed.25047497.s14.e1" /></sentence><sentence text="5 and 1" /><sentence text="0 hours after dosing, respectively" /><sentence text=" The mean (SD) AUC∞ values were 532 (117) ng·h/mL and 405 (110) ng·h/mL, respectively" /><sentence text=" Although the Cmax was not significantly affected, the geometric mean ratio for AUC∞ was increased by a point estimate of 1" /><sentence text="33 (90% CI, 1" /><sentence text="23-1" /><sentence text="44)" /><sentence text=" A single oral administration of lobeglitazone 0"><entity charOffset="33-46" id="DDI-PubMed.25047497.s22.e0" text="lobeglitazone" /></sentence><sentence text="5 mg with or without ketoconazole pretreatment did not produce any clinically significant adverse effects on vital signs, 12-lead ECG profiles, or laboratory tests"><entity charOffset="21-33" id="DDI-PubMed.25047497.s23.e0" text="ketoconazole" /></sentence><sentence text="" /><sentence text="The administration of lobeglitazone, 0"><entity charOffset="22-35" id="DDI-PubMed.25047497.s25.e0" text="lobeglitazone" /></sentence><sentence text="5 mg alone or in combination with multiple doses of ketoconazole, was generally well tolerated"><entity charOffset="52-64" id="DDI-PubMed.25047497.s26.e0" text="ketoconazole" /></sentence><sentence text=" The systemic exposure of lobeglitazone was increased to a modest extent by pretreatment with 9 twice-daily doses of ketoconazole"><entity charOffset="26-39" id="DDI-PubMed.25047497.s27.e0" text="lobeglitazone" /><entity charOffset="117-129" id="DDI-PubMed.25047497.s27.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.25047497.s27.e0" e2="DDI-PubMed.25047497.s27.e0" /><pair ddi="false" e1="DDI-PubMed.25047497.s27.e0" e2="DDI-PubMed.25047497.s27.e1" /></sentence><sentence text=" Clinicaltrials" /><sentence text="gov identifier: NCT01330563" /><sentence text="" /></document>